Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopeniaKarina Althaus, Tamam Bakchoul, Hans Henkes et al.|Haematologica|2021Cited by 136
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, Saurabh Dahiya et al.|Nature Medicine|2024Cited by 127
Current treatment of mantle cell lymphoma: results of a national survey and consensus meetingMathias Witzens‐Harig, M. Dreyling, J. Atta et al.|Annals of Hematology|2012Cited by 13
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)Catherine Thiéblemont, Nathan Fowler, M. Dreyling et al.|Hematological Oncology|2025Cited by 1